Tecovirimat is under clinical development by SIGA Technologies and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tecovirimat’s likelihood of approval (LoA) and phase transition for Monkeypox took place on 15 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tecovirimat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tecovirimat overview

Tecovirimat (Tpoxx / ST-246) is an antiviral agent. It is formulated as hard gelatin capsules for oral route of administration and injectable solution for intravenous route of administration. Tecovirimat (Tpoxx) is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg. Tecovirimat is inidcated for the treatment of viral infections include smallpox, monkeypox and cowpox in adults and children with body weight at least 13 kg, and also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg.

Tecovirimat (ST-246) is under development for the treatment and prophylaxis of orthopoxviruses, smallpox and monkeypox. It is administered intravenously and orally as a capsule and liquid solution. It was also under development as a liquid formulation for the treatment and prophylaxis of cowpox and vaccinia infections mallpox in pediatric patients.

SIGA Technologies overview

SIGA Technologies (SIGA) is a company that provides health security services. The company develops and commercialise solutions for serious unmet medical needs and bio threats. It offers antiviral drug to treat smallpox disease. SIGA offers product such as TPOXX. The company’s Tecovirimat is combined with smallpox vaccines to prevent disease and reduce vaccine-related complications. It also develops orally administered small molecule therapeutics for the treatment and prevention of disease caused by virus. The company provides research and development, and preclinical model services. SIGA is headquartered in New York City, New York, the US.

Quick View Tecovirimat LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Tecovirimat
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.